Contact
![](/sites/default/files/styles/medium_220px_width/public/2020-11/nahiaprueba_0.jpg?itok=lGhKXjfl)
Diario Médico reports on work presented by Valeria Fantin, Director of the Biology Dept. of Agios Pharmeceuticals, at the Barcelona Biomed Conference “Cancer Metabolism”, held from 8-10 November and organised by IRB Barcelona. The study opens up new avenues for the treatment of some kind of cancer, such a gliomas and acute myloid leukemia.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).